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Abstract
Background: Bone metastasis is relatively uncommon in gastric cancer patients, but its incidence has been rising.
Early detection of bone metastasis is important in preventing complications related to bone metastasis such as
pain, fracture and the compromise of chemotherapy. In this pilot study, we investigated the feasibility of bone
turnover markers as surrogate markers of bone metastasis in gastric cancer patients.
Methods: Fifty-eight patients with gastric cancer were included in this study. Serum levels of bone alkaline
phosphatase (ALP), parathyroid hormone (PTH), 25(OH) D, osteocalcin (OC) and C terminal telopeptide were
measured and compared between patients with bone metastasis and those without. Student’s t-test and
Mann-Whitney U test were used in comparing two groups, and Spearman’s rank order correlation coefficient was
calculated to quantify the strength of the associations.
Results: Fifty eight age- and sex-matched patients were evaluated for bone turnover markers, among whom 29
patients had bone metastasis and 29 patients with no bone metastasis. The median age was 62 and there were 20
(68.9 %) males and 9 (31.1 %) females in each group. Bone ALP was significantly higher in the patient group (57.32
± 46.83 vs. 34.57 ± 21.57, P = 0.037) than control group. Bone ALP was positively associated with ALP, osteocalcin,
CA19-9, CA 72–4 and negatively associated with 25(OH) D. According to ROC-curve analysis, at the threshold value
of 29.60 μg/L, the sensitivity of bone ALP was 76.7 % and the specificity was 59.4 %.
Conclusion: Bone ALP may be a surrogate marker of bone metastasis in gastric cancer patients. More prospective
studies are warranted to determine the optimal bone turnover markers in the evaluation of bone metastasis.
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Background
Bone metastasis occurs frequently in patients with ad-
vanced breast, prostate, lung, and kidney cancers, but is
known to be less frequent in cancers arising from
gastrointestinal tract [1]. Bone metastasis in gastric can-
cer is thus relatively uncommon, and there are only a
few studies on the incidence, clinical presentation and
prognosis of gastric cancer patients with bone
metastasis. To date, the incidence of bone metastasis
varies from 1 to 45 % from the few previous studies
[2–4]. However, due to wide use of imaging diagnos-
tics and longer survival of gastric cancer patients, the
incidence of bone metastasis is increasing. The prog-
nosis of patients with bone metastasis is very dismal
[2, 5], and thus, there is a need to detect develop-
ment of bone metastasis at an early stage. Since com-
monly used tumor markers in gastric cancers (CEA,
CA 19–9, CA 72–4) cannot accurately predict the
tumor burden in bone, other predictive serum
markers for bone metastasis are required.
Bone metastasis results in disruption of normal
homeostasis of bone, which is a dynamic process
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involving osteoclast-mediated osteolysis and osteoblast-
mediated osteogenesis. This may result in reduced bone
integrity and skeletal complications such as fracture and
severe bone pain may occur [6]. Paraneoplastic syn-
dromes such as hypercalcemia associated with bone me-
tastasis may be life-threatening. Therefore, early
detection of bone metastasis in advanced cancer patients
is important for treatment and prognosis. The assess-
ment of bone metastasis currently relies on imaging, and
99mTc-based bone scintigraphy is routinely used for the
detection of bone metastasis [7]. Although bone scintig-
raphy is highly sensitive, its specificity is low [8], and it
is not cost-effective to repeat bone scintigraphy in order
to detect bone metastases early in patients without bone
metastasis. In addition, bone scintigraphy is not largely
recommended as routine evaluation for evidence of bone
metastasis at the time of diagnosis or during treatment.
The use of bone turnover markers has been investi-
gated for diagnostic and prognostic purposes in ad-
vanced cancer patients. Bone formation markers are
direct or indirect products of osteoblast activity, whereas
bone resorption markers are derived from the degrad-
ation of skeletal collagen. Bone markers have been ex-
tensively studied in prostate cancers, and several studies
have assessed the diagnostic efficacy of bone formation
and resorption markers for detecting bone metastases
[9–12]. Bone alkaline phosphatase (ALP) is an indicator
of osteoblast metabolism, and it is relatively a specific
marker for osteogenesis. Osteocalcin is the non-collagen
protein of bone matrix, and is released during matrix
synthesis and circulates in blood. C-terminal telopeptide
(CTX) is a carboxy terminal peptide of mature type I
collagen, and is released during bone resorption. Para-
thyroid hormone (PTH) may stimulate bone resorption
by binding to osteoblasts to increase expression of
RANKL and the binding of RANKL to RANK stimulates
osteoclast, which ultimately enhances bone resorption
[13]. 25(OH)D stimulates bone resorption by aiding dif-
ferentiation of osteoclast progenitors to osteoclasts [14].
In this pilot study, we compared the five bone turn-
over markers in gastric cancer patients with or without
bone metastasis. We aimed to develop surrogate mea-
surements that might provide a useful complement to
established imaging techniques for identifying patients
with skeletal involvement.
Methods
Patient selection
This is a cross-sectional study for examining the role of
bone markers in advanced gastric cancer patients from
March, 2013 to March 2014 at Yonsei Cancer Center.
Patient eligibility criteria were as following: 1) age ≥ 20;
2) advanced or metastatic gastric cancer patients; 3)
known status of bone metastasis; 4) patients who
provided informed consent. Patients were divided into
two groups, one group with bone metastasis (patient
group) and the other group without bone metastasis
(control group) for comparison.
Measurement of bone markers
Serum PTH was measured using an immunochemilumi-
nescence assay for intact PTH. Serum 25(OH)D was
measured by radioimmunoassay, and osteocalcin was
measured by an electrochemiluminescence immunoassay
method (Roche Diagnostics, Mannheim, Germany). CTx
was measured by one-step ELISA and bone ALP was
measured by electrochemiluminescent ELISA immuno-
assay (UnicelDxl 800, Beckman Coulter, USA).
Diagnosis of bone metastasis
To identify bone metastasis, radiographic imaging mo-
dalities including radionuclide bone scintigraphy, plain
radiography, CT and magnetic resonance imaging were
used in all patients. Bone scitigraphy was performed 4 h
after intravenous injection with 99mTc-labeled methyldi-
phosphonate, and a gamma camera was used for record-
ing. Simple radiographs, CT or magnetic resonance
imaging were secondarily performed to confirm abnor-
mal findings on bone scintigraphy and clinical symptoms
including bone pain and paralysis. In patients with an
2[18F] Fluoro-2-deoxy-D-glucose (FDG) -PET scan
showing abnormal uptake, bone scan and radiographs
were performed to confirm the presence of metastatic
lesions in needed.
Statistical analysis
Patients were matched according to age and sex using
propensity score matching. Patients were grouped as de-
scribed above and the data was analyzed using SPSS v
20.0 software. The results were examined by comparing
the value of bone markers in the groups with or without
bone metastasis. For all parameters, mean ± standard de-
viation values were used. Paired-t test was performed to
compare the markers between two groups, and Pearson’s
correlation was calculated to quantify the strength of the
associations. Sensitivity, specificity, positive predictive
and negative predictive values aimed at detecting the
diagnostic value of bone markers were calculated using
ROC analysis. In all analysis, P < 0.05 was considered
statistically significant.
Results
Baseline characteristics of patients
A total of fifty eight age- and sex-matched patients were
evaluated and baseline characteristics of patient and
control groups are shown in Table 1. There were 29 pa-
tients in each group and the median age was 62. There
were 20 (68.9 %) males and 9 (31.1 %) females in each
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group. When the baseline characteristics were com-
pared, only ECOG performance status was different be-
tween the two groups. The control group had more PS 0
patients than the patient group (P < 0.001). The most
common site of bone metastases was pelvis (62.5 %),
then vertebra (62.1 %) and rib (62.1 %), arm-shoulder
(37.9 %), femur (37.9 %), cranial (3.4 %), in the order of
frequency (Additional file 1: Table S1).
Comparison of patient and control groups
Bone turnover markers were compared between patient
and control groups (Table 2). Among the five markers,
bone ALP was significantly higher in the patient group
(57.32 ± 46.83 vs. 34.57 ± 21.57, P = 0.037) than control
group. Serum osteocalcin and CTx were higher and
25(OH) D and PTH were lower in the patient group, but
they did not reach a statistical significance. The com-
parison of bone ALP between two groups is shown in
Fig. 1 as a scatter plot. When other serum markers such
as LDH, calcium, CEA, CA19-9 and CA72-4 were com-
pared between patients with bone metastasis and control
groups, there were no significant differences between
the two groups.
Correlation between bone alkaline phosphatase and
serum markers
Then, we analyzed the correlation between bone ALP
and other bone turnover markers and serum markers.
Bone ALP was positively associated with ALP, osteocalcin,
CA19-9, CA72-4 and negatively associated with 25(OH) D.
There was no significant correlation between bone ALP
with CTx, PTH, LDH, calcium and CEA level (Table 3).
We also analyzed correlation between bone ALP and
SUV uptake by PET-CT. With 13 patients who under-
went PET-CT at diagnosis, we could not find a signifi-
cant relationship between serum levels of bone ALP and
the maximum value of FDG uptake (Pearson’s correlate
coefficient 0.161, P = 0.60).
Diagnostic performance of bone markers
The best overall diagnostic performance for discriminat-
ing patients with bone metastases was provided by bone
ALP assay, followed closely by PTH and CTx, and then
by osteocalcin and 25(OH) D, in the order of diagnostic
validity. The area under the ROC curve was 0.662, 0.542,
0.520, 0.484, and 0.474, respectively (Fig. 2). According
to ROC-curve analysis, the sensitivity of bone ALP was
Table 1 Baseline characteristics of all patients (N = 58)
Characteristics Patient (n = 29) Control (n = 29) P
Age, years (median) 62 62 1.00a
Sex
Male 20 20 1.00a
Female 9 9
Initial staging 0.05
I 0 1
II 1 4
III 5 11
IV 23 13
ECOG performance status <0.001
0 11 24
1 18 5
Surgery history 0.08
Yes 13 19
No 16 9
aAge and sex-matched by propensity score matching
Significant P-values in bold letters
Table 2 Distribution of marker values between patient and
control groups
Mean ± SD Patient (n = 29) Control (n = 29) P
Osteocalcin (ng/mL) 25.55 ± 4.15 26.42 ± 3.33 0.881
Bone ALP (μg/L) 57.32 ± 46.83 34.57 ± 21.57 0.037
CTx (ng/mL) 1.19 ± 1.73 0.74 ± 0.32 0.193
25 (OH)D(ng/mL) 12.72 ± 7.44 12.06 ± 5.54 0.717
PTH (pg/mL) 42.97 ± 14.70 54.44 ± 57.26 0.350
Analyzed by paired t-test
SD standard deviation, ALP alkaline phosphatase, CTx serum collagen type 1
cross-linked C-telopeptide, PTH parathyroid hormone
Significant P-values in bold letters
Fig. 1 Comparison of bone ALP levels in patient and control groups.
Bone ALP was significantly higher in the patient group (57.32 ± 46.83
vs. 34.57 ± 21.57, P = 0.037) than control group
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Table 3 Correlation between bone ALP and other serum markers
ALP Osteocalcin CTx 25(OH) D PTH LDH Calcium CEA CA19-9 CA72-4
c P c P c P c P c P c P c P c P c P c P
Bone ALP 0.584 <0.001 0.335 0.011 −0.022 0.867 −0.315 0.022 0.253 0.065 −0.031 0.821 0.016 0.904 0.161 0.226 0.342 0.009 0.344 0.011
Analyzed by Spearman’s correlation
c correlation coefficient
Significant P-values in bold letters
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76.7 % and the specificity was 59.4 % at the threshold
value of 29.60 μg/L. When bone ALP values were di-
chotomized by the threshold value, there were 24 pa-
tients (82.7 %) with high bone ALP values in the patient
group, whereas 12 patients (41.3 %) had high values in
the control group. We also examined to find the best
combination of predictive markers by using logistic re-
gression model, but addition of other bone turnover
markers did not produce an addictive diagnostic value
for bone metastasis.
Patient cases
Here, we introduce two patient cases that suggest the
feasibility of bone ALP as a predictive marker of bone
metastasis and treatment response. The first patient is a
47-year-old female patient who was initially grouped as
the control group without known bone metastasis.
Serum bone ALP was 19.1 μg/L at baseline (May 2013),
and was given palliative chemotherapy with 5-
fluorouracil and docetaxel combination. When she com-
pleted 6 cycles of chemotherapy, her bone ALP was in-
creased to 26.9 μg/L. There was no documented bone
metastasis on the bone scan taken in October, 2013 and
the disease was maintained stable on abdomen CT with-
out clinical deterioration. She was continued on the
chemotherapy, but when she underwent follow up im-
aging evaluation in December, 2013, the bone scan re-
vealed multiple bone metastases at T-, L-spine and
sacrum, bilateral rib cage, left scapula, and both left
ileum. Her bone ALP increased further to 43.0 μg/L.
This case shows the potential of bone ALP as an early
predictor of bone metastasis in patients without docu-
mented bone metastasis (Fig. 3a).
Next is a 64-year-old male patient diagnosed with
multiple bone metastases at bilateral ribs, both pelvic
bones and femurs. His bone ALP was initially 43.8 μg/L.
He underwent palliative chemotherapy with TS-1 plus
oxaliplatin, and after 3 cycles, his tumor showed favor-
able response to therapy and bone metastatic lesions
showed a decrease in intensity on the bone scan. In
addition, bone ALP was decreased to 26.7 μg/L after
3 cycles. This case suggests that bone ALP may be a
monitoring marker of response to systemic chemother-
apy (Fig. 3b).
Discussion
This is a pilot study of evaluating the feasibility of bone
turnover markers for detecting bone metastasis in gas-
tric cancer patients. To our knowledge, this is the first
study to evaluate the diagnostic value of bone turnover
markers in gastric cancer patients. Our hypothesis was
whether bone turnover markers can differentiate pa-
tients with or without bone metastases. Bone ALP was
significantly higher in the group with bone metastasis
compared to those without metastasis. Bone ALP was
positively associated with ALP, osteocalcin, CA19-9, CA
72–4 and was negatively associated with 25(OH) D. Ac-
cording to ROC-curve analysis, at the threshold value of
29.60 μg/L, the sensitivity of bone ALP was 76.7 % and
the specificity was 59.4 %.
Fig. 2 Receiver operating characteristics curves of bone metastasis according to five bone turnover markers. The best overall diagnostic
performance for discriminating patients with bone metastases was provided by bone ALP assay, followed closely by PTH and CTx, and then by
osteocalcin and 25(OH) D, in the order of diagnostic validity. The area under the ROC curve was 0.662, 0.542, 0.520, 0.484, and 0.474, respectively
Lim et al. BMC Cancer  (2016) 16:385 Page 5 of 7
Bone ALP is one of the several isoforms of ALP that
are secreted by various organs including liver, intestine
and placenta [15]. It is specifically present on the surface
of osteoblasts, and serum level of bone ALP was shown
to have a linear relationship with osteoblast and osteo-
blastic precursor activity [16]. Although the diagnostic
value of bone ALP has not been studied in gastric can-
cer, bone ALP was found significant in predicting bone
metastasis in patients with breast and prostate cancer
[17]. A study by Bomabardieri et al. showed that bone
ALP was the best marker to discriminate bone scan
positive patients from scan-negative breast cancer pa-
tients [18]. Demers LM et al. showed that bone ALP
showed a significant correlation with both the presence
of bone metastases and the extent of skeletal involve-
ment in metastatic cancer patients. Moreover, levels of
bone ALP were significantly higher with blastic disease
presentation than with the presence of either lytic or
mixed disease [19].
The two cases presented here reveal the feasibility of
bone ALP as a useful complement for monitoring pro-
gression of bone disease. First case suggests that serum
bone ALP level may begin to increase before bone me-
tastasis is detectable through standard imaging tech-
niques, and continue to rise until metastasis becomes
visible. Whether bone ALP can be used to determine
early bone micrometastases before shown on bone scan
still remains to be determined. However, there is
evidence that bone ALP might represent disease exten-
sion [19], and clinicians may infer the risks of disease
progression and future skeletal complications. Second
case provides prognostic information regarding the re-
sponse of bone disease to systemic therapy. Thus, these
findings provide evidence for the potential of bone ALP
to reflect not only the presence, but also the extent of
bone metastasis.
This study has a few limitations. First of all, it is a
cross-sectional study and it may not reflect the continu-
ous renewal of osteoclasts and osteoblasts. Previous
studies reported that osteolytic type of bone metastasis
is more common than osteoblastic or mixed type (52 vs.
22.8 vs. 25.2 %) [20], and thus the marker of osteolysis
remains to be identified. Secondly, the sample size of
this study is small, and a larger-scaled study is required
to conclude the utility of bone ALP as compared to
other bone turnover markers. Lastly, the sensitivity
(76.7 %) and specificity (59.4 %) of bone ALP at the
threshold value of 29.60 μg/L are not very high.
Conclusion
In conclusion, levels of bone ALP appear to be the most
predictive biochemical markers for the presence of bone
metastases in gastric cancer patients. There is also pre-
liminary evidence that the level correlates with the ex-
tent of metastatic disease. However, prospective studies
are needed to examine whether this marker can be
Fig. 3 a A 47-year-old female patient with no known bone metastasis at baseline subsequently developed multiple bone metastases at spine
and sacrum, rib cage, left scapula, and left ileum. Serum bone ALP levels increased from 19.1 μg/L to 43.0 μg/L. b A 64-year-old male patient
initially diagnosed with multiple bone metastases showed favorable response to chemotherapy. The bone metastatic lesions showed a decrease
in intensity on bone scintigraphy and bone ALP level was decreased after 3 months of chemotherapy
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validated in a larger number of patients. In addition, fu-
ture investigations are warranted to see whether bone
turnover markers can be used to guide clinicians in de-
termining the effectiveness of therapy in gastric cancer
patients with bone metastases.
Additional file
Additional file 1: Table S1. Sites of bone metastasis. (DOCX 14 kb)
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